19 May 2013
Keywords: Anthera Pharma, Varespladib, Cardiovascular events, ACS
Article | 12 March 2012
US development-stage biophama company Anthera Pharmaceuticals (Nasdaq: ANTH) saw its shares plunge as much as 65% to $2.25 in after-hours trading on ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscriptions are £60 per month, pay as you go.
Find out more details.
12 March 2012
17 May 2013
© 2013 thepharmaletter.com